158. 結節性硬化症 Disease details / Clinical trials / Drug dev / DR info

Acetate
   Brigham and Women's Hospital
      2021   Phase 1/Phase 2   NCT05467397   United States
AED
   Peking Union Medical College Hospital
      2017   Phase 2   NCT03356769   China
Afinitor
   Cardiff University
      2012   Phase 2   EUCTR2011-004854-25-GB   United Kingdom
   Novartis Pharma Services AG
      -   Phase 3   EUCTR2008-002113-48-DE   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2010-022583-13-FR   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain
Afinitor 5MG tablets
   Novartis Pharma Services AG
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
Aspirin
   Peking Union Medical College Hospital
      2017   Phase 2   NCT03356769   China
Basimglurant
   Noema Pharma
      -   Phase 2   EUCTR2021-000838-34-PL   India;Israel;Italy;Poland;Spain;Türkiye;United Kingdom;United States
   Noema Pharma AG
      2023   Phase 2   EUCTR2021-000838-34-IT   Australia;Israel;Italy;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 2   NCT05059327   Australia;India;Israel;Italy;Poland;Spain;Turkey;United Kingdom;United States
Buccal (cheek) swab
   National Tuberous Sclerosis Association
      2016   -   NCT05676099   Canada;United States
Bumetanide
   UMC Utrecht
      2017   Phase 2   EUCTR2016-002408-13-NL   Netherlands
Cannabidiol
   Amsterdam UMC
      2025   Phase 3   EUCTR2021-003250-23-NL   Netherlands
   GW Research Ltd
      -   Phase 3   EUCTR2020-002132-67-Outside-EU/EEA   United States
   GW Research Ltd.
      2017   Phase 3   EUCTR2015-002154-12-NL   Australia;Netherlands;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002154-12-ES   Australia;France;Netherlands;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2015-002154-12-PL   Australia;Netherlands;Poland;Spain;United Kingdom;United States
   Jazz Pharmaceuticals
      2023   Phase 4   NCT05864846   Canada;Poland;United Kingdom;United States
      2021   Phase 4   NCT05044819   United States
Carbon dioxide
   The First Hospital of Hebei Medical University
      2022   Phase 0   ChiCTR2200055795   China
CBD
   GW Research Ltd
      -   Phase 3   EUCTR2020-002132-67-Outside-EU/EEA   United States
   GW Research Ltd.
      2017   Phase 3   EUCTR2015-002154-12-NL   Australia;Netherlands;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002154-12-ES   Australia;France;Netherlands;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2015-002154-12-PL   Australia;Netherlands;Poland;Spain;United Kingdom;United States
Certican 1 MG tablets
   Novartis Pharma Services AG
      2011   -   EUCTR2007-006997-27-BE   Belgium;Germany;Italy;Netherlands;United Kingdom
Doxycycline
   University of Nottingham
      2009   Phase 4   NCT00989742   United Kingdom
Epidiolex 100 MG/ML oral solution
   Jazz Pharmaceuticals
      2025   -   NCT05485831   Italy
Everolimus
   Cardiff University
      2012   Phase 2   NCT01954693   United Kingdom
      2012   Phase 2   EUCTR2011-004854-25-GB   United Kingdom
   Children's Hospital Medical Center, Cincinnati
      2010   Phase 1/Phase 2   NCT01070316   United States
      2008   Phase 1/Phase 2   NCT00792766   United States
      2007   Phase 1/Phase 2   NCT00411619   United States
   Dana-Farber Cancer Institute
      2014   Phase 2   NCT02201212   United States
   Department of Pharmacy, Peking University First Hospita
      2020   Phase 4   ChiCTR2000039523   China
   Department of Urology, Keio University School of Medicine
      2013   -   JPRN-UMIN000011559   Japan
   Erasmus MC - Department of Neurology
      2012   Phase 2   EUCTR2010-019519-39-NL   Netherlands
   Erasmus Medical Center
      2012   Phase 2/Phase 3   NCT01730209   Netherlands
   General Hospital of PLA
      2016   -   ChiCTR-OPN-16008236   China
   Hospices Civils de Lyon
      2020   Phase 2/Phase 3   NCT02860494   France
      2018   Phase 2;Phase 3   EUCTR2018-002531-18-FR   France
   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      2013   Phase 2   NCT01929642   United States
   NOVARTIS FARMA
      2013   Phase 3   EUCTR2011-000860-90-IT   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-022583-13-IT   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
      2009   -   EUCTR2008-002113-48-IT   France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2007-006997-27-IT   Belgium;Germany;Italy;Netherlands;United Kingdom
   NOVARTIS PHARMA AG
      2019   Phase 3   EUCTR2016-002977-37-IT   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   NYU Langone Health
      2014   Phase 2   NCT02451696   United States
   Novartis Farmacéutica S.A
      2017   Phase 3   EUCTR2016-002977-37-ES   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2013   Phase 3   EUCTR2011-000860-90-ES   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2017   Phase 3   EUCTR2016-002977-37-HU   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002977-37-GB   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002977-37-FR   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002977-37-BE   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2016-002977-37-PL   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Novartis Pharma Services AG
      2014   Phase 3;Phase 4   EUCTR2013-003795-13-BE   Belgium;Canada;Poland;Russian Federation;United States
      2014   Phase 3   EUCTR2011-000860-90-IE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-NL   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-HU   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-GR   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-GB   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-DK   Argentina;Belgium;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Taiwan;Turkey;United Kingdom
      2013   Phase 3   EUCTR2011-000860-90-BE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-022583-13-HU   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
      2011   -   EUCTR2010-022583-13-GR   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
      2011   Phase 3   EUCTR2010-022583-13-CZ   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain
      2011   Phase 3   EUCTR2010-022583-13-BE   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
      2011   -   EUCTR2007-006997-27-BE   Belgium;Germany;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2008-002113-48-NL   France;Germany;Italy;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2007-006997-27-NL   Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom
      2010   -   EUCTR2007-006997-27-DE   Belgium;Germany;Italy;Netherlands;United Kingdom
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   EUCTR2008-002113-48-FR   France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   Phase 3   EUCTR2007-006997-27-GB   Belgium;Germany;Italy;Netherlands;United Kingdom
      -   Phase 3   EUCTR2010-022583-13-FR   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain
      -   Phase 3   EUCTR2008-002113-48-DE   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2013-003795-13-PL   Belgium;Canada;Poland;Russian Federation;United States
      -   -   EUCTR2010-022583-13-DE   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
   Novartis Pharmaceuticals
      2023   Phase 4   NCT05252585   Taiwan
      2018   Phase 4   NCT03525834   China
      2017   Phase 3   NCT02962414   Australia;Belgium;Canada;Colombia;France;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2009   Phase 3   NCT00790400   Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   NCT00789828   Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States
   West China hospital, Sichuan University
      2025   -   ChiCTR2500095913   China
Everolimus 2MG dispersible tablet
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2011-000860-90-DE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Everolimus oral product
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States
Ganaxalone
   Marinus Pharmaceuticals
      2022   Phase 3   NCT05323734   Australia;Canada;China;France;Germany;Israel;Italy;Spain;United Kingdom;United States
Ganaxolone
   Marinus Pharmaceuticals
      2022   Phase 3   NCT05604170   Australia;Belgium;Canada;China;France;Germany;Israel;Italy;Spain;United Kingdom;United States
      2020   Phase 2   NCT04285346   United States
   Marinus Pharmaceuticals Inc.
      2022   Phase 3   EUCTR2021-003441-38-ES   Belgium;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003441-38-DE   Australia;Belgium;Canada;China;France;Germany;Israel;Italy;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2021-003441-38-FR   Belgium;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States
   Marinus Pharmaceuticals, Inc
      -   Phase 3   EUCTR2021-003441-38-IT   Belgium;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States
   Marinus Pharmaceuticals, Inc.
      -   Phase 3   EUCTR2021-003441-38-BE   Australia;Belgium;Canada;China;France;Germany;Israel;Italy;Spain;United Kingdom;United States
GWP42003-P
   GW Research Ltd
      -   Phase 3   EUCTR2020-002132-67-Outside-EU/EEA   United States
   GW Research Ltd.
      2017   Phase 3   EUCTR2015-002154-12-NL   Australia;Netherlands;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-002154-12-ES   Australia;France;Netherlands;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2015-002154-12-PL   Australia;Netherlands;Poland;Spain;United Kingdom;United States
   Jazz Pharmaceuticals
      2021   Phase 3   NCT04485104   Italy;Spain;United States
      2016   Phase 3   NCT02544763   Australia;Netherlands;Poland;Spain;United Kingdom;United States
L04aa18
   Erasmus MC - Department of Neurology
      2012   Phase 2   EUCTR2010-019519-39-NL   Netherlands
Metformin hydrochloride
   University Hospitals Bristol NHS Foundation Trust
      2012   Phase 4   EUCTR2011-001319-30-GB   United Kingdom
NOE-101
   Noema Pharma
      -   Phase 2   EUCTR2021-000838-34-PL   India;Israel;Italy;Poland;Spain;Türkiye;United Kingdom;United States
   Noema Pharma AG
      2023   Phase 2   EUCTR2021-000838-34-IT   Australia;Israel;Italy;Poland;Spain;Turkey;United Kingdom;United States
NPC-12G GEL
   Nobelpharma
      2015   Phase 3   NCT02635789   Japan
      2015   Phase 3   NCT02634931   Japan
NPC-12Y GEL
   Nobelpharma
      2022   Phase 3   NCT05495425   Japan
Petrolatum
   Department of Dermatology Graduate School of Medicine, Osaka University
      2009   Phase 2,3   JPRN-UMIN000002844   Japan
Phlebotomy
   National Tuberous Sclerosis Association
      2016   -   NCT05676099   Canada;United States
Propranolol
   University Hospital, Bordeaux
      2015   Phase 2   NCT02104011   France
RAD001
   Cardiff University
      2012   Phase 2   NCT01954693   United Kingdom
      2012   Phase 2   EUCTR2011-004854-25-GB   United Kingdom
   Children's Hospital Medical Center, Cincinnati
      2008   Phase 1/Phase 2   NCT00792766   United States
      2005   Phase 1/Phase 2   NCT00457964   United States
   Mustafa Sahin
      2011   Phase 2   NCT01289912   United States
   NOVARTIS FARMA
      2013   Phase 3   EUCTR2011-000860-90-IT   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-022583-13-IT   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
      2009   -   EUCTR2008-002113-48-IT   France;Germany;Italy;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2007-006997-27-IT   Belgium;Germany;Italy;Netherlands;United Kingdom
   NOVARTIS PHARMA AG
      2019   Phase 3   EUCTR2016-002977-37-IT   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica S.A
      2017   Phase 3   EUCTR2016-002977-37-ES   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2013   Phase 3   EUCTR2011-000860-90-ES   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2017   Phase 3   EUCTR2016-002977-37-HU   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002977-37-GB   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002977-37-FR   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002977-37-BE   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2016-002977-37-PL   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Novartis Pharma Services AG
      2014   Phase 3;Phase 4   EUCTR2013-003795-13-BE   Belgium;Canada;Poland;Russian Federation;United States
      2014   Phase 3   EUCTR2011-000860-90-IE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-NL   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-HU   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-GR   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-GB   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-DK   Argentina;Belgium;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Taiwan;Turkey;United Kingdom
      2013   Phase 3   EUCTR2011-000860-90-DE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-BE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-022583-13-HU   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
      2011   -   EUCTR2010-022583-13-GR   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
      2011   Phase 3   EUCTR2010-022583-13-CZ   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain
      2011   Phase 3   EUCTR2010-022583-13-BE   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
      2011   -   EUCTR2007-006997-27-BE   Belgium;Germany;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2008-002113-48-NL   France;Germany;Italy;Netherlands;Spain;United Kingdom
      2010   -   EUCTR2007-006997-27-NL   Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
      2009   Phase 3   EUCTR2008-002113-48-FR   France;Germany;Italy;Netherlands;Spain;United Kingdom
      -   Phase 3   EUCTR2013-003795-13-PL   Belgium;Canada;Poland;Russian Federation;United States
      -   Phase 3   EUCTR2010-022583-13-FR   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain
   Novartis Pharmaceuticals
      2013   Phase 3   NCT01713946   Argentina;Australia;Belgium;Canada;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
      2009   Phase 3   NCT00790400   Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
RAD001 1MG
   Novartis Pharma Services AG
      2010   -   EUCTR2007-006997-27-DE   Belgium;Germany;Italy;Netherlands;United Kingdom
RAD001 2,5 MG
   Novartis Pharma Services AG
      -   -   EUCTR2010-022583-13-DE   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
RAD001 5MG
   Novartis Pharma Services AG
      -   Phase 3   EUCTR2008-002113-48-DE   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States
RAD001 round tablets
   Novartis Pharma Services AG
      2009   Phase 3   EUCTR2007-006997-27-GB   Belgium;Germany;Italy;Netherlands;United Kingdom
Radiprodil
   GRIN Therapeutics, Inc.
      2024   Phase 1/Phase 2   NCT06392009   Australia;Belgium;Canada;Italy;Netherlands;Poland;Spain;United Kingdom
Radiprodil + CO-administered drugs
   GRIN Therapeutics, Inc.
      2025   Phase 1   NCT06975605   Australia
Radiprodil with carbamazepine
   GRIN Therapeutics, Inc.
      2025   Phase 1   NCT06965881   Australia
Radiprodil with itraconazole
   GRIN Therapeutics, Inc.
      2025   Phase 1   NCT06965881   Australia
Rapamune
   Erasmus MC
      2011   Phase 2   EUCTR2010-022655-29-NL   Netherlands
   FUNDACIÓ PUIGVERT
      2008   -   EUCTR2007-005978-30-ES   Spain
   Le Bonheur Children's Hospital
      2013   Phase 1   NCT01853423   United States
Rapamune 1 MG/ML oral solution
   The Children's Memorial Health Institute
      -   Phase 3   EUCTR2021-004548-64-PL   Poland
      -   Phase 2;Phase 3   EUCTR2020-003231-19-PL   Poland
Rapamune 1 MG/ML solucióN oral
   Fundación Investigación Hospital Ramón y Cajal
      2012   -   EUCTR2011-006308-12-ES   Spain
Rapamycin
   Chinese PLA General Hospital
      2015   -   ChiCTR-OOB-15006535   China
   Department of Dermatology Graduate School of Medicine, Osaka University
      2014   Phase 2,3   JPRN-UMIN000015114   Japan
      2011   Phase 2,3   JPRN-UMIN000006108   Japan
   Department of Dermatology Graduate School of Medicine, Osaka University
      2009   Phase 2,3   JPRN-UMIN000002844   Japan
   Dermatology Specialties Limited Partnership
      2019   Phase 2/Phase 3   NCT03826628   Australia;Czechia;Hungary;New Zealand;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States
   Katarzyna Kotulska
      2023   Phase 3   NCT05534672   Poland
      2021   Phase 2/Phase 3   NCT04987463   Poland
   The University of Texas Health Science Center, Houston
      2012   Phase 2   NCT01526356   Australia;United States
Rapamycin cream, topical, 0.5%, 1.0% W/W
   DSLP
      2019   Phase 2;Phase 3   EUCTR2019-000752-34-SK   Australia;Czech Republic;Hungary;New Zealand;Slovakia;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000752-34-HU   Australia;Hungary;New Zealand;Slovakia;Spain;United Kingdom;United States
   Dermatology Specialities Limited Partnership (DSLP)
      -   Phase 2;Phase 3   EUCTR2019-000752-34-CZ   Australia;Czech Republic;Hungary;New Zealand;Serbia;Slovakia;Spain;United States
Rapamycin, sirolimus
   Children's Hospital Medical Center, Cincinnati
      2002   Phase 2   NCT00457808   United States
Rapamycin-calcitriol combination
   National Taiwan University Hospital
      2013   Phase 3   NCT03140449   -
Sabril 500 MG, granules FOR oral solution
   The Children's Memorial Health Institute
      -   Phase 2;Phase 3   EUCTR2020-003231-19-PL   Poland
Sertraline
   Anagnostou, Evdokia, M.D.
      2024   Phase 2   NCT06081348   Canada
Simvastatin
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States
Sirolimus
   Aucta Pharmaceuticals, Inc
      2017   Phase 2   NCT03363763   China;United States
   Cardiff University
      2005   Phase 2   NCT00490789   United Kingdom
   Children's Hospital Medical Center, Cincinnati
      2020   Phase 1/Phase 2   NCT04595513   United States
   DSLP
      2019   Phase 2;Phase 3   EUCTR2019-000752-34-SK   Australia;Czech Republic;Hungary;New Zealand;Slovakia;Spain;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000752-34-HU   Australia;Hungary;New Zealand;Slovakia;Spain;United Kingdom;United States
   Darcy Krueger
      2021   Phase 2   NCT05104983   United States
   Department of Dermatology Graduate School of Medicine, Osaka University
      2013   Phase 1,2   JPRN-UMIN000012420   Japan
   Dermatology Specialities Limited Partnership (DSLP)
      -   Phase 2;Phase 3   EUCTR2019-000752-34-CZ   Australia;Czech Republic;Hungary;New Zealand;Serbia;Slovakia;Spain;United States
   FUNDACIÓ PUIGVERT
      2008   -   EUCTR2007-005978-30-ES   Spain
   Fundacio Puigvert
      2008   Phase 4   NCT01217125   -
   Fundación Investigación Hospital Ramón y Cajal
      2012   -   EUCTR2011-006308-12-ES   Spain
   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      2013   Phase 2   NCT01929642   United States
   West China Hospital, Sichuan University
      2020   -   ChiCTR2000031984   China
Sirolimus oral product
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States
Skincerity plus sirolimus/rapamycin
   The University of Texas Health Science Center, Houston
      2009   Phase 1   NCT01031901   United States
Skinercity plus sirolimus/rapamycin
   The University of Texas Health Science Center, Houston
      2009   Phase 1   NCT01031901   United States
Tacrolimus
   Department of Dermatology Graduate School of Medicine, Osaka University
      2009   Phase 2,3   JPRN-UMIN000002844   Japan
Tissue donation after routine clinical procedure
   National Tuberous Sclerosis Association
      2016   -   NCT05676099   Canada;United States
Turmeric
   NYU Langone Health
      2018   -   NCT03254680   United States
Vigabatrin
   Katarzyna Kotulska
      2021   Phase 2/Phase 3   NCT04987463   Poland
   Martina Bebin
      2016   Phase 2   NCT02849457   United States
   The Children's Memorial Health Institute
      2014   Phase 4   EUCTR2013-005528-40-NL   Belgium;Netherlands
   University of Pennsylvania
      2010   Phase 4   NCT01266291   United States
   Vrije Universiteit Brussel
      2014   Phase 4   EUCTR2013-005528-40-BE   Belgium;Netherlands
Votubia
   Erasmus MC - Department of Neurology
      2012   Phase 2   EUCTR2010-019519-39-NL   Netherlands
   NOVARTIS PHARMA AG
      2019   Phase 3   EUCTR2016-002977-37-IT   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   Novartis Farmacéutica S.A
      2017   Phase 3   EUCTR2016-002977-37-ES   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2017   Phase 3   EUCTR2016-002977-37-HU   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002977-37-GB   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002977-37-FR   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002977-37-BE   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      -   Phase 3   EUCTR2016-002977-37-PL   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
   Novartis Pharma Services AG
      2014   Phase 3;Phase 4   EUCTR2013-003795-13-BE   Belgium;Canada;Poland;Russian Federation;United States
      2014   Phase 3   EUCTR2011-000860-90-IE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-NL   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-HU   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-GB   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2011-000860-90-DK   Argentina;Belgium;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Taiwan;Turkey;United Kingdom
      2013   Phase 3   EUCTR2011-000860-90-BE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2010-022583-13-BE   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain
      -   Phase 3   EUCTR2013-003795-13-PL   Belgium;Canada;Poland;Russian Federation;United States